Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
L-2-18F-FAMP is an L-enantiomeric, 2-position, 18F-fluoro-α-methyl-phenylalanine derivative developed as a tumor imaging agent for positron emission tomography (PET). It is a radiolabeled synthetic amino acid specifically taken up by the L-type amino acid transporter 1 (LAT1), which is highly expressed in many types of tumors. Preclinical PET imaging with L-2-18F-FAMP in tumor xenograft models demonstrates high and selective tumor uptake, rapid blood clearance, and lower renal background signal than older tracers. These properties suggest L-2-18F-FAMP offers improved tumor visualization and pharmacokinetics compared to existing radiolabeled amino acid tracers[4]. The agent functions as a radiopharmaceutical PET tracer for oncology imaging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-2-18F-FAMP.